Subgroup analysis revealed that the experimental group was significantly more effective in reducing IL-6 levels in both ARS [SMD = ‐2.19, 95% CI (‐2.92, ‐1.47), P < .00001] and CRS [SMD = ‐1.40, 95% CI (‐1.79, ‐1.01), P < .00001] when compared to their respective control groups. The gene discussed is IL6; the disease is Axenfeld-Rieger syndrome.